NMJ Mullaney_14.01.25

The Neuromuscular Junction

  • Dr. Ian Mullaney: Senior Lecturer in Medical Sciences at QMUL Malta

  • Date: 20th January 2025

Intended Learning Objectives

  • Understand the anatomy of the neuromuscular junction (NMJ)

  • Understand the physiology of the NMJ

  • Understand the pharmacology of the NMJ

Contents Overview

  • Neuronal control of skeletal muscles

  • The neuromuscular junction

    • Pre-synaptic

    • Synaptic

    • Post-synaptic

  • Pharmacology of the neuromuscular junction and pathophysiology of NMJ disorders

Neuronal Control of Skeletal Muscles

The Neuron

  • Primary Signalling Unit: Mediates instructions between brain and peripheral tissues

  • Structure and Function:

    • Electrically Excitable: Processes and transmits information through signals

    • Action Potentials: Electrochemical pulses lasting <1 ms, traveling along axons at 1-100 m/s

    • Neurons can emit action potentials consistently or sporadically.

Synapses

  • Axonal Transmission:

    • Axons form synaptic connections (

    • Each axon may connect to thousands of other cells.

  • Neurotransmitter Release:

    • Action potentials trigger neurotransmitter release from synapses,

    • Neurotransmitters bind to receptor molecules in target cells.

  • Synaptic Connections:

    • Estimated 100 trillion synapses in the human brain.

Neurons in Network

  • Neurons communicate via chemical and electrical signals in networks,

  • Cerebral Cortex: Contains 15-33 billion neurons, interconnected by synapses.

Nervous System Overview

Anatomical Divisions

  • Central Nervous System (CNS): Brain and spinal cord

  • Peripheral Nervous System (PNS): Nerves outside CNS, includes:

    • Afferent Division: Carries signals to CNS

    • Efferent Division: Carries signals away from CNS, subdivided into:

      • Somatic Division: Voluntary muscle control

      • Autonomic Division: Involuntary regulation (smooth muscle, cardiac muscle, glands)

Components of Autonomic Division

  • Sympathetic and Parasympathetic Divisions: Manage involuntary functions through two-neuron chains.

Cortical Homunculus

  • Representation of Body: Distorted map indicating brain areas for sensory and motor functions,

  • Motor Homunculus: Addresses motor processing in the primary motor cortex (precentral gyrus),

  • Sensory Homunculus: Associated with sensory processing in the primary sensory cortex (postcentral gyrus).

Anatomy of the Motor Neuron

Upper and Lower Motor Neurons

  • Upper Motor Neurons: Originates in motor cortex (precentral gyrus) and descends through corticospinal tract.

  • Lower Motor Neurons: Originates in spinal cord, innervating muscle fibers; includes alpha motor neurons in the ventral horn of the spinal cord.

Motor Unit Dynamics

  • Motor Unit: Comprises a motor neuron and the muscle fibers it innervates,

  • NMJ Functionality: One NMJ typically connects to one muscle fiber, enabling precise transmission of signals from the brain to muscle contractions.

Neuronal Signaling Process

Mechanisms of Action

  1. Electrical Signal Movement: Charge travels along the axon,

  2. Neurotransmitter Activity: Release and uptake of neurotransmitters at NMJ.

Synthesis and Role of Acetylcholine (ACh)

  • Synthesis Process:

    • ACh synthesized from choline in lower motor neurons,

    • Stored in vesicles until needed for neurotransmission.

  • Release Mechanism: A complex process involving Ca2+ activation triggers vesicle fusion, releasing ACh into the junctional space.

Post-Junctional Effects

  • ACh Receptor Mechanism: ACh binds to nicotinic receptors on muscle membrane, resulting in contraction,

  • Acetylcholinesterase Role: Breaks down excess ACh in junction to cease action.

Modulation of NMJ Function

Modulatory Factors

  • Environmental Factors: Toxins affecting NMJ integrity,

  • Pathological Conditions: Diseases like Myasthenia Gravis,

  • Pharmacological Agents: Drugs affecting ACh dynamics.

Key Toxins and Their Effects

  • Botulinum Toxin: Prevents ACh release, used therapeutically for various conditions,

  • Omega Conotoxin: Blocks calcium channels, used for severe pain treatment.

  • Alpha Latrotoxin: Increases transmitter release, ultimately leading to depletion of ACh.

Pathological Conditions

  1. Myasthenia Gravis: Autoimmune disorder blocking NMJ communication, treatment includes acetylcholinesterase inhibitors.

Pharmacological Agents

  • Nicotinic Receptor Agonists and Antagonists: Influence muscle contraction and relaxation,

  • Acetylcholinesterase Inhibitors: Prolong the action of ACh at the NMJ, aiding conditions like myasthenia gravis.

Summary of Drugs Discussed

  • Drugs and Mechanisms:

    • Acetylcholine: Neuromuscular interactions,

    • Botulinum Toxin: ACh release blockade,

    • Omega Conotoxin: Calcium channel inhibition,

    • D-tubocurarine: Non-depolarizing muscle relaxant,

    • Succinylcholine: Rapid-acting depolarizing muscle relaxant,

    • Neostigmine: ACh level maintenance in myasthenia gravis.